Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018204713) TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/204713 International Application No.: PCT/US2018/030978
Publication Date: 08.11.2018 International Filing Date: 03.05.2018
IPC:
A61K 31/135 (2006.01) ,A61K 31/138 (2006.01) ,A61K 31/215 (2006.01) ,A61K 31/485 (2006.01) ,A61P 25/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
138
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
485
Morphinan derivatives, e.g. morphine, codeine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
VEPACHEDU, Sreenivasarao [US/US]; US
EXCIVA UG (HAFTUNGSBESCHRÄNKT); Am Aukopf 14/1 69118 Heidelberg, DE
Inventors:
VEPACHEDU, Sreenivasarao; US
MOEBIUS, Hans J.; CH
BESPALOV, Anton; DE
Agent:
VEPACHEDU, Sreenivasarao [US/US]; US
Priority Data:
10612916928.08.2017TW
62/501,69604.05.2017US
62/634,16222.02.2018US
62/635,55427.02.2018US
62/636,09927.02.2018US
62/636,17128.02.2018US
PCT/US2017/04874825.08.2017US
Title (EN) TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF
(FR) TARGETED DRUG RESCUE AVEC DE NOUVELLES COMPOSITIONS, ASSOCIATIONS ET PROCÉDÉS CORRESPONDANTS
Abstract:
(EN) Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, wherein the compound is double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided.
(FR) L'invention concerne des composés de la formule I, des sels pharmaceutiquement acceptables de ces derniers, leurs énantiomères, leurs métabolites, leurs dérivés, leurs promédicaments, leurs sels pharmaceutiquement acceptables, leurs N-oxydes, ou une association de ces derniers, des procédés et des intermédiaires pour leur préparation, des compositions les contenant, et leurs utilisations. L'invention concerne des compositions pharmaceutiques comprenant un composé de la formule I, ou ses énantiomères, ses métabolites, ses dérivés, ses promédicaments, ses sels d'addition d'acide, ses sels pharmaceutiquement acceptables, ou ses N-oxydes, ou une association de ces derniers, le composé étant un agent ou un ligand double et/ou un triple pour les récepteurs CYP2D6, 5-HT2A et/ou 5 HT2C, et/ou l'acétylcholinestérase.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)